Overview

Levetiracetam in the Treatment of Neuroleptic-induced Tardive Dyskinesia

Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
An 8-week study to examine safety and efficacy of levetiracetam in patients with neuroleptic-induced tardive dyskinesia
Phase:
Phase 2
Details
Lead Sponsor:
UCB Pharma
Treatments:
Antipsychotic Agents
Etiracetam
Levetiracetam
Piracetam